DP
PDLI

Dearborn Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Dearborn Partners’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-69,590
Closed -$490K – 294
2015
Q1 		$490K Sell
69,590
-21,499
-24% -$156K 0.04% 214
2014
Q4 		$702K Buy
91,089
+46,322
+103% +$367K 0.06% 190
2014
Q3 		$334K Buy
44,767
+9,360
+26% +$86.9K 0.03% 247
2014
Q2 		$343K Sell
35,407
-5,095
-13% -$45.4K 0.03% 239
2014
Q1 		$337K Buy
40,502
+6,654
+20% +$57K 0.04% 232
2013
Q4 		$286K Sell
33,848
-27,216
-45% -$229K 0.03% 257
2013
Q3 		$487K Hold
61,064
– – 0.06% 207
2013
Q2 		$471K Buy
+61,064
New +$476K 0.07% 203

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dearborn Partners's PDLI Position: Q2 2015 in Review

Dearborn Partners sold out of PDL BioPharma, Inc. (PDLI) in Q2 2015, closing a stake of 69,590 shares — an estimated $490K sold.

Dearborn Partners first reported a position in PDLI in Q2 2013 and held it in 8 quarters. The position peaked at $702K in Q4 2014. 204 funds tracked by Wall St. Rank hold PDLI as of Q2 2015.

  • Dearborn Partners reported no remaining PDL BioPharma, Inc. position as of Q2 2015 after selling out during the quarter.
  • Dearborn Partners sold 69,590 PDL BioPharma, Inc. shares in Q2 2015, an estimated $490K.
  • Dearborn Partners first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 8 quarters.
  • Dearborn Partners's PDL BioPharma, Inc. position peaked at $702K in Q4 2014.
  • 204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2015.

Based on Dearborn Partners's 13F filing for Q2 2015, filed 13 Aug 2015.